Selecting patients for idarucizumab (Praxbind)

Arrhythmia

Sponsored by Boehringer Ingelheim Pty Ltd

2 Nov 2016

In the final video of the series Professor Pollack takes us through interim results from RE-VERSE AD which identified the types of patients suitable for dabigatran reversal with idarucizumab (Praxbind).

Already a member?

Login to keep reading.

Email me a login link

Not a member yet?

Join now to stay up to date with the latest clinical and medico-political news relevant to your specialty. the limbic is intended for practicing healthcare professionals only.

title*

first name*

last name*

country*

Postcode where you practice*

Email*

password* Forgot password?

Password must contain at least 8 characters including 1 letter and 1 number.

ahpra number* Find my AHPRA number

primary area of interest*

Our newsletter is a quick and easy to read summary of the latest clinical and medico-political news relevant to your specialty. It may contain advertising and educational or promotional material from carefully selected industry partners including pharmaceutical companies, government agencies and not-for-profit organisations. Your details will not be shared with any other party.

I would like to receive the limbic newsletter

I have read and agree to the limbic Terms and Conditions & Privacy Policy

SEARCH

CATEGORIES

About

Search

Account

Saved

SEARCH

CATEGORIES

Selecting patients for idarucizumab (Praxbind)

Arrhythmia

Already a member?

Not a member yet?

Log in

SEARCH

CATEGORIES

About

Search

Account

Saved

SEARCH

CATEGORIES

Selecting patients for idarucizumab (Praxbind)

Arrhythmia

Already a member?

Not a member yet?

Selecting patients for idarucizumab (Praxbind)